Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,716.19 +700.48 (+1.11%) CMC Crypto 200
1,325.05 +48.07 (+3.76%)
BIO Jun 2024 440.000 call
| Previous close | 2.6500 |
| Open | 2.6500 |
| Bid | 0.1000 |
| Ask | 9.7000 |
| Strike | 440.00 |
| Expiry date | 2024-06-21 |
| Day's range | 2.6500 - 2.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
ZacksEarnings Preview: National Vision (EYE) Q1 Earnings Expected to Decline
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireBio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
HERCULES, Calif., May 01, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern Time (11:05 AM Pacific Time).
ZacksAnalysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
